We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other best mid ...

Immunovant develops monoclonal antibody therapeutics, with batoclimab as its lead candidate targeting autoimmune diseases such as myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic ...

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.

The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. Roivant reported that its revenue for the period was slightly under $2.2 billion, ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the best biotech stocks to invest in now. On June 16, Pulmovant, a Roivant company, announced the publication of Phase 1 pharmacokinetic/PK data for ...

On Wednesday, Roivant Sciences Ltd. (NASDAQ:ROIV) posted fourth-quarter adjusted earnings per share of $0.28, far surpassing analyst expectations of a $0.29 loss per share. However, quarterly revenue ...

Roivant financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to ...

Roivant Sciences stock performance snapshot Roivant Sciences (ROIV) has drawn investor attention recently after its share price closed at US$29.96, with total return around 9% over the past month and ...

Tuesday's raiser was Leerink Partners prognosticator David Risinger. Well before market open, he added $1 to his Roivant price target for a new level of $18 per share. In doing so, he maintained his ...

Transaction value based on SEC Form 4 reported price ($21.00); post-transaction value based on Dec. 12, 2025 market close, yielding a position value of $2,993,835,324.94. Immunovant, Inc. is a ...